BEHRENS, F., P. C. TAYLOR, D. WETZEL, N. C. BRUN, J. BRANDT-JUERGENS, E. DRESCHER, Eva DOKOUPILOVÁ, A. ROWINSKA-OSUCH, N. Abdel-Kader MARTIN and K. DE VLAM. IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY. 2022. ISSN 0003-4967. Available from: https://dx.doi.org/10.1136/annrheumdis-2022-eular.536.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY
Authors BEHRENS, F., P. C. TAYLOR, D. WETZEL, N. C. BRUN, J. BRANDT-JUERGENS, E. DRESCHER, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), A. ROWINSKA-OSUCH, N. Abdel-Kader MARTIN and K. DE VLAM.
Edition 2022.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 27.400
RIV identification code RIV/00216224:14160/22:00128084
Organization unit Faculty of Pharmacy
ISSN 0003-4967
Doi http://dx.doi.org/10.1136/annrheumdis-2022-eular.536
UT WoS 000850279000259
Keywords in English Izokibep; ABY-035; psoriatic arthriris; clinical trial
Tags rivok, ÚFT
Tags International impact
Changed by Changed by: JUDr. Sabina Krejčiříková, učo 383857. Changed: 19/1/2023 09:27.
Abstract
Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with heterogenous musculoskeletal manifestation (arthritis, spondylitis, enthesitis, dactylitis) and extra-musculoskeletal manifestation (skin and nail psoriasis). In addition, PsA is commonly associated with comorbidities such as metabolic syndrome and cardiovascular diseases where IL-17 is a key driver of this disease. Izokibep is a unique IL-17A inhibitor with extraordinary potency and small molecular size designed to overcome the limitations of monoclonal antibodies such as poor tissue distribution. Here, we report 16-week phase 2 results in patients with active PsA.
PrintDisplayed: 29/7/2024 14:17